Verition Fund Management’s Nurix Therapeutics NRIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-30,405
Closed -$738K – 2288
2026
Q2
$738K Buy
+30,405
New +$518K ﹤0.01% 1536
2026
Q1
– Sell
-68,754
Closed -$1.3M – 3144
2025
Q4
$1.3M Buy
+68,754
New +$988K 0.01% 1948
2025
Q3
– Sell
-41,922
Closed -$477K – 3931
2025
Q2
$477K Buy
+41,922
New +$453K ﹤0.01% 2968
2025
Q1
– Sell
-31,396
Closed -$592K – 3590
2024
Q4
$592K Buy
+31,396
New +$720K ﹤0.01% 2374
2024
Q2
– Sell
-13,175
Closed -$194K – 3179
2024
Q1
$194K Buy
+13,175
New +$142K ﹤0.01% 2506

Other funds holding NRIX

Verition Fund Management's NRIX Position: Q3 2026 in Review

Verition Fund Management sold out of Nurix Therapeutics (NRIX) in Q3 2026, closing a stake of 30,405 shares — an estimated $738K sold.

Verition Fund Management first reported a position in NRIX in Q1 2024 and held it in 5 quarters. The position peaked at $1.3M in Q4 2025. 233 funds tracked by Wall St. Rank hold NRIX as of Q3 2026.

  • Verition Fund Management reported no remaining Nurix Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Verition Fund Management sold 30,405 Nurix Therapeutics shares in Q3 2026, an estimated $738K.
  • Verition Fund Management first reported a position in Nurix Therapeutics in Q1 2024 and held it in 5 quarters.
  • Verition Fund Management's Nurix Therapeutics position peaked at $1.3M in Q4 2025.
  • 233 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2026.

Based on Verition Fund Management's 13F filing for Q3 2026, filed 13 Nov 2026.